Stroke · 2018 · 195 citations · 26 references
Life SciencesImmunologyPharmacotherapyImmunotherapyInflammationNeuroimmunologyAcute InflammationAcute Ischemic StrokeCerebrovascular DiseaseInflammatory BiomarkersNeuroinflammationStrokeAcute Ischemic Stroke InterventionAcute Ischemic Stroke ThrombolysisAcute Ischemic Stroke TreatmentInflammatory Cytokine EffectsIschemic Stroke PrognosticationNeuroinflammation In StrokeProinflammatory Cytokine ModulationStroke Neuroprotection
Background and Purpose— The proinflammatory cytokine IL-1 (interleukin-1) has a deleterious role in cerebral ischemia, which is attenuated by IL-1 receptor antagonist (IL-1Ra). IL-1 induces peripheral inflammatory mediators, such as interleukin-6, which are associated with worse prognosis after ischemic stroke. We investigated whether subcutaneous IL-1Ra reduces the peripheral inflammatory response in acute ischemic stroke. Methods— SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke) was a single-center, double-blind, randomized, placebo-controlled phase 2 trial of subcutaneous IL-1Ra (100 mg administered twice daily for 3 days) in patients presenting within 5 hours of ischemic stroke onset. Randomization was stratified for baseline National Institutes of Health Stroke Scale score and thrombolysis. Measurement of plasma interleukin-6 and other peripheral inflammatory markers was undertaken at 5 time points. The primary outcome was difference in concentration of log(interleukin-6) as area under the curve to day 3. Secondary outcomes included exploratory effect of IL-1Ra on 3-month outcome with the modified Rankin Scale. Results— We recruited 80 patients (mean age, 72 years; median National Institutes of Health Stroke Scale, 12) of whom 73% received intravenous thrombolysis with alteplase. IL-1Ra significantly reduced plasma interleukin-6 ( P <0.001) and plasma C-reactive protein ( P <0.001). IL-1Ra was well tolerated with no safety concerns. Allocation to IL-1Ra was not associated with a favorable outcome on modified Rankin Scale: odds ratio (95% confidence interval)=0.67 (0.29–1.52), P =0.34. Exploratory mediation analysis suggested that IL-1Ra improved clinical outcome by reducing inflammation, but there was a statistically significant, alternative mechanism countering this benefit. Conclusions— IL-1Ra reduced plasma inflammatory markers which are known to be associated with worse clinical outcome in ischemic stroke. Subcutaneous IL-1Ra is safe and well tolerated. Further experimental studies are required to investigate efficacy and possible interactions of IL-1Ra with thrombolysis. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: ISRCTN74236229
26
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
Haichao Wang, Ona Bloom, Minghuang Zhang et al. · Science · 1999 · 3.4K citations
Hemorrhagic Transformation Within 36 Hours of a Cerebral Infarct
Marco Fiorelli, Stefano Bastianello, Rüdiger von Kummer et al. · Stroke · 1999 · 758 citations · Full text
Medicine, Neurology, Neuroscience +17
Early Intrathecal Production of Interleukin-6 Predicts the Size of Brain Lesion in Stroke
E. Tarkowski, Lars Rosengren, Christian Blomstrand et al. · Stroke · 1995 · 390 citations
Life Sciences, Immunology, Neurology +17